Article in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Julie M JornsDepartment of Pathology, Froedtert and Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0002-7777-6670
Yunguang SunDepartment of Pathology, Froedtert and Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0003-4004-9514
Sailaja KamarajuDivision of Hematology and Oncology, Department of Medicine, Froedtert and Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0003-3031-9269
Yee Chung ChengDivision of Hematology and Oncology, Department of Medicine, Froedtert and Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Amanda KongDivision of Surgical Oncology, Department of Surgery, Froedtert and Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Tina YenDivision of Surgical Oncology, Department of Surgery, Froedtert and Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0001-7210-4333
Caitlin R PattenDivision of Surgical Oncology, Department of Surgery, Froedtert and Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Chandler S CortinaDivision of Surgical Oncology, Department of Surgery, Froedtert and Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0002-4750-5028
Christopher R ChitambarDivision of Hematology and Oncology, Department of Medicine, Froedtert and Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Hallgeir RuiDepartment of Pharmacology, Physiology & Cancer Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19144, USA.
Lubna N ChaudharyDivision of Hematology and Oncology, Department of Medicine, Froedtert and Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0003-0616-6135
Funding
Institutional Career Development CoreKL2TR001438 · NCATS · MEDICAL COLLEGE OF WISCONSIN · PI WIDLANSKY, MICHAEL E · 2015 to 2024
$2.9M
WNT pathway-driven anti-estrogen therapy resistance in breast cancerR01CA267549 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Inna Chervoneva, Hallgeir Rui · 2023 to 2026
$2.2M
Understanding the Influence of Hormone Therapy on Breast Cancer Risk and Screening through Mixed MethodsK08CA276706 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Chandler Scott Cortina · 2023 to 2026
$841k
Quantitative Analyses of HER2 Upregulation in Luminal Breast Cancer in Response to Neoadjuvant Endocrine TherapyR03CA259594 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI CHAUDHARY, LUBNA N., RUI, HALLGEIR · 2021 to 2022
PD-L1 immunohistochemistry (IHC) has become an established method for predicting cancer response to targeted anti-PD1 immunotherapies, including breast cancer (BC). The alternative PD-1 ligand, PD-L2, remains understudied but may be a complementary predictive marker. Prospective analysis of 32 breast cancers revealed divergent expression patterns of PD-L1 and PD-L2. PD-L1-positivity was higher in immune cells than in cancer cells (median = 5.0% vs. 0.0%;
Indexed as
breast cancerimmune checkpoint inhibitionimmunohistochemistryPD-L1PD-L2
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Divergent Cellular Expression Patterns of PD-L1 and PD-L2 Proteins in Breast Cancer. · full record | OpenQuestion